PDCD1 and neoplasm: In our analysis, approximately 10.6% of MSS tumor samples showed both high TME1.TcellInfiltration scores and high TME2.TcellResponse scores, suggesting the biological characteristics of tumor microenvironments in 10.6% of MSS patients can still potentially benefit from anti-PD1 treatment.